Drug news: Pfizer's JAK-3 inhibitor

I've run across just a couple of bits and scraps about this but thought it looked interesting.

For background, Pfizer's JAK-e inhibitor is an immunosuppressant, ref. this recent abstract:

CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. (May 2009 study from Current Opinion in Investigative Drugs)

...And they seem to be further along with it clinically than others. Then tucked in a news clip on August 25:

In the area of dry eye, a JAK-3 inhibitor, originally investigated as a systemic medication for rheumatoid arthritis and transplant rejection, has been reformulated as a topical eye drop.

Sounds like a wannabe Restasis competitor if it comes together. I will be interested to see more on this one and will keep you posted.